Risk of Chronic Kidney Disease in 260 Patients with Lupus Nephritis: Analysis of a Nationwide Multicentre Cohort with Up to 35 Years of Follow-up

Overview

Journal Rheumatology (Oxford)

Publisher Oxford University Press

Specialty Rheumatology

Date 2024 Apr 22

PMID 38648778

Authors

Filipa Farinha

Sofia Barreira

Maura Couto

Margarida Cunha

Diogo Fonseca

Raquel Freitas

Luis Ines

Mariana Luis

Carla Macieira

Ana R Prata

Joana Rodrigues

Bernardo Santos

Rita Torres

Ruth J Pepper

Anisur Rahman

Maria J Santos

Affiliations

Soon will be listed here.

Abstract

Objectives: To compare proliferative (PLN) and membranous (MLN) lupus nephritis (LN) regarding clinical and laboratory presentation and long-term outcomes, and to investigate predictors of progression to chronic kidney disease (CKD).

Methods: Multicentre observational study, with retrospective analysis of a prospective cohort, using data from the Rheumatic Diseases Portuguese Registry - Reuma.pt. Patients with biopsy-proven PLN, MLN and mixed LN were included. Cox regression survival analysis was used to investigate predictors of CKD.

Results: A total of 260 patients were included. Median follow-up was 8 years (IQR 11; minimum 1, maximum 35 years). MLN patients presented with significantly lower serum creatinine [0.70 (IQR 0.20; minimum 0.50, maximum 1.30) mg/dl vs 0.80 (IQR 0.31; minimum 0.26, maximum 2.60) in PLN, P = 0.003]. Proteinuria levels did not differ between groups (P = 0.641). Levels of complement were reduced in PLN but nearly normal in MLN patients, and there were fewer patients with positive anti-dsDNA antibodies in the MLN group (P < 0.001). One year after the beginning of treatment, 62% of the patients achieved EULAR/ERA-EDTA complete response, with a further 5% achieving partial response. Patients with lower proteinuria at diagnosis were more likely to achieve a complete renal response at one year; however, proteinuria at diagnosis or at one year did not predict long-term CKD. Estimated glomerular filtration rate (eGFR) ≤75 mL/min/1.73 m2 at one year was the strongest predictor of progression to CKD (HR 23 [95% CI 8-62], P < 0.001). Other possible predictors included the use of azathioprine for induction of remission, older age at diagnosis and male sex.

Conclusion: Proteinuria levels did not predict LN histologic class in our cohort. eGFR cutoff of 75 mL/min/1.73 m2 after one year of treatment was strongly predictive of progression to CKD.

References

Ahn S, Yoo J, Jung S, Song J, Park Y, Lee S . Comparison of clinical features and outcomes between patients with early and delayed lupus nephritis. BMC Nephrol. 2020; 21(1):258. PMC: 7341643. DOI: 10.1186/s12882-020-01915-5. View

Ikeuchi H, Sugiyama H, Sato H, Yokoyama H, Maruyama S, Mukoyama M . A nationwide analysis of renal and patient outcomes for adults with lupus nephritis in Japan. Clin Exp Nephrol. 2022; 26(9):898-908. DOI: 10.1007/s10157-022-02232-x. View

Farinha F, Pepper R, Oliveira D, McDonnell T, Isenberg D, Rahman A . Outcomes of membranous and proliferative lupus nephritis - analysis of a single-centre cohort with more than 30 years of follow-up. Rheumatology (Oxford). 2020; 59(11):3314-3323. PMC: 7590413. DOI: 10.1093/rheumatology/keaa103. View

Hanly J, OKeeffe A, Su L, Urowitz M, Romero-Diaz J, Gordon C . The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford). 2015; 55(2):252-62. PMC: 4939728. DOI: 10.1093/rheumatology/kev311. View

Zickert A, Sundelin B, Svenungsson E, Gunnarsson I . Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med. 2014; 1(1):e000018. PMC: 4213828. DOI: 10.1136/lupus-2014-000018. View

Pineiro G, Arrizabalaga P, Sole M, Abellana R, Espinosa G, Cervera R . Repeated Renal Biopsy - A Predictive Tool to Assess the Probability of Renal Flare in Lupus Nephritis. Am J Nephrol. 2016; 44(6):439-446. DOI: 10.1159/000452229. View

Ikeuchi H, Hiromura K, Kayakabe K, Tshilela K, Uchiyama K, Hamatani H . Renal outcomes in mixed proliferative and membranous lupus nephritis (Class III/IV + V): A long-term observational study. Mod Rheumatol. 2016; 26(6):908-913. DOI: 10.3109/14397595.2016.1158896. View

Petri M, Orbai A, Alarcon G, Gordon C, Merrill J, Fortin P . Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012; 64(8):2677-86. PMC: 3409311. DOI: 10.1002/art.34473. View

Ortega L, Schultz D, Lenz O, Pardo V, Contreras G . Review: Lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus. 2010; 19(5):557-74. DOI: 10.1177/0961203309358187. View

10.

Gisca E, Duarte L, Farinha F, Isenberg D . Assessing outcomes in a lupus nephritis cohort over a 40-year period. Rheumatology (Oxford). 2020; 60(4):1814-1822. DOI: 10.1093/rheumatology/keaa491. View

11.

De Rosa M, Azzato F, Toblli J, De Rosa G, Fuentes F, Nagaraja H . A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int. 2018; 94(4):788-794. DOI: 10.1016/j.kint.2018.05.021. View

12.

Maningding E, DallEra M, Trupin L, Murphy L, Yazdany J . Racial and Ethnic Differences in the Prevalence and Time to Onset of Manifestations of Systemic Lupus Erythematosus: The California Lupus Surveillance Project. Arthritis Care Res (Hoboken). 2019; 72(5):622-629. PMC: 6872905. DOI: 10.1002/acr.23887. View

13.

Morales E, Galindo M . SGLT2 inhibitors in lupus nephropathy, a new therapeutic strategy for nephroprotection. Ann Rheum Dis. 2022; 81(9):1337-1338. DOI: 10.1136/annrheumdis-2022-222512. View

14.

Suzuki E, Yashiro-Furuya M, Temmoku J, Fujita Y, Matsuoka N, Hazama M . Comparison of renal remission and relapse-free rate in initial- and delayed-onset lupus nephritis. Int J Rheum Dis. 2021; 24(12):1500-1509. PMC: 9292939. DOI: 10.1111/1756-185X.14228. View

15.

Delfino J, Dos Santos T, Skare T . Comparison of lupus patients with early and late onset nephritis: a study in 71 patients from a single referral center. Adv Rheumatol. 2020; 60(1):5. DOI: 10.1186/s42358-019-0105-5. View

16.

Kwon O, Park J, Lee S, Song J, Park Y, Park M . Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis. Yonsei Med J. 2020; 61(11):951-957. PMC: 7593100. DOI: 10.3349/ymj.2020.61.11.951. View

17.

Fanouriakis A, Kostopoulou M, Cheema K, Anders H, Aringer M, Bajema I . 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020; 79(6):713-723. DOI: 10.1136/annrheumdis-2020-216924. View

18.

Mejia-Vilet J, Cordova-Sanchez B, Uribe-Uribe N, Correa-Rotter R . Immunosuppressive treatment for pure membranous lupus nephropathy in a Hispanic population. Clin Rheumatol. 2016; 35(9):2219-27. DOI: 10.1007/s10067-016-3366-y. View

19.

Ahn S, Yoo J, Lee S, Song J, Park Y, Jung S . Clinical characteristics and long-term outcomes in patients with mixed Class III/IV + V and pure proliferative lupus nephritis: A single-center experience. Lupus. 2022; 31(5):588-595. DOI: 10.1177/09612033221088437. View

20.

Hanaoka H, Iida H, Kiyokawa T, Takakuwa Y, Kawahata K . Early achievement of deep remission predicts low incidence of renal flare in lupus nephritis class III or IV. Arthritis Res Ther. 2018; 20(1):86. PMC: 5932878. DOI: 10.1186/s13075-018-1576-1. View